# 2025年12月18日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 线粒体对脓毒症诱导性心肌病中乳酰化的调控机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408319)
**期刊：** Critical care (London, England)
**PMID：** 41408319
**DOI：** 10.1186/s13054-025-05802-z

### 第一部分 原文与翻译

**英文原标题：** Mitochondrial regulation of lactylation in sepsis-induced cardiomyopathy.

> **英文摘要：**
> Sepsis-induced cardiomyopathy (SICM) is a life-threatening complication of sepsis that is characterized by acute cardiac dysfunction and is associated with high mortality. Despite advances in detection techniques that have improved the identification of myocardial abnormalities, the link between these findings and effective therapeutic strategies remains poorly defined. Mitochondrial dysfunction-through its roles in metabolic reprogramming, oxidative stress, and calcium dysregulation-has emerged as a central feature and putative driver of SICM. Recently, lactylation, a lactate-derived posttranslational modification, has been identified as a key mechanism amplifying inflammatory and metabolic dysfunction under these conditions. However, a comprehensive understanding of how mitochondrial dysregulation is mechanistically linked to lactylation and how this axis contributes to the progression of SICM is still lacking. This review aims to synthesize current evidence on the mitochondrial regulation of lactylation in SICM, elucidate the underlying molecular pathways, and evaluate potential therapeutic interventions targeting this axis. By integrating mechanistic insights from preclinical and clinical studies, we seek to bridge the gap between mitochondrial biology and epigenetic metabolic regulation, with the goal of informing future research and improving clinical outcomes in SICM.

> **中文摘要：**
> 脓毒症诱导性心肌病（SICM）是脓毒症的一种危及生命的并发症，其特征为急性心脏功能障碍，并伴随高死亡率。尽管检测技术的进步提高了心肌异常的识别率，但这些发现与有效治疗策略之间的联系仍不清晰。线粒体功能障碍——通过其在代谢重编程、氧化应激和钙调节失衡中的作用——已成为SICM的核心特征和推定驱动因素。近期研究发现，乳酰化是一种源自乳酸的蛋白质翻译后修饰，在这些条件下被鉴定为放大炎症和代谢功能障碍的关键机制。然而，目前仍缺乏关于线粒体失调如何在机制上与乳酰化相联系，以及该通路如何促进SICM进展的全面理解。本综述旨在综合当前关于SICM中线粒体调控乳酰化的研究证据，阐明潜在的分子通路，并评估针对该轴的潜在治疗干预。通过整合来自基础和临床研究的机制性见解，本研究期望弥合线粒体生物学与表观遗传代谢调控之间的鸿沟，以期为未来研究提供指导并改善SICM的临床结局。

### 第二部分 AI 大师评价

该综述聚焦脓毒症诱导性心肌病中线粒体功能障碍与乳酰化之间的分子联系，系统整合了现有的基础与临床研究证据。文章突出线粒体在代谢重编程及炎症信号调控中的核心作用，并探讨乳酰化这一新兴表观代谢机制在疾病进展中的潜在作用。作者提出以线粒体-乳酰化轴为新靶点的治疗策略，为精准干预SICM提供了新的思路。其创新性在于将线粒体代谢与表观修饰机制相结合，但仍需更多实验证据验证其因果关系及临床可行性。

---

## 2. S100B 触发神经内分泌-巨噬细胞网络以驱动小鼠气道再生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408059)
**期刊：** Nature communications
**PMID：** 41408059
**DOI：** 10.1038/s41467-025-67691-8

### 第一部分 原文与翻译

**英文原标题：** S100B triggers neuroendocrine macrophage networks to drive airway regeneration in mice.

> **英文摘要：**
> The mammalian airway epithelium contains specialized cells that detect and respond to environmental injury, yet the mechanisms that coordinate epithelial repair remain poorly defined. Pulmonary neuroendocrine cells act as neurosensory sentinels within this epithelium and can reprogram to support regeneration. Here we show that the calcium-binding protein S100B is essential for maintaining the stem cell-like properties of pulmonary neuroendocrine cells during airway repair. Following epithelial injury, S100B expression is induced in these cells and released to engage macrophages that express the enzyme arginase-1, which in turn promotes the expansion of pulmonary neuroendocrine cells and their transition into regenerative intermediate cells. Modulating S100B activity, either by blocking S100B with pentamidine or by enhancing signaling driven by the protein kinase p110-alpha in airway epithelial cells, alters the reparative capacity of pulmonary neuroendocrine cells. These findings identify an S100B-arginase-1 signaling axis that governs macrophage-epithelial communication and highlight S100B as a potential therapeutic target for lung repair.

> **中文摘要：**
> 哺乳动物的气道上皮包含能够检测并响应环境损伤的特化细胞，但协调上皮修复的机制仍然知之甚少。肺部神经内分泌细胞在该上皮中充当神经感觉哨兵，并可重新编程以支持再生。在本研究中，我们发现钙结合蛋白 S100B 对于维持气道修复过程中肺神经内分泌细胞的干样特性至关重要。在上皮损伤后，这些细胞中 S100B 的表达被诱导并释放，以激活表达精氨酸酶-1 的巨噬细胞，而后者反过来促进肺神经内分泌细胞的扩增及其向再生中间细胞的转变。通过调节 S100B 活性——无论是使用潘他脒阻断 S100B，还是增强由蛋白激酶 p110-α 驱动的气道上皮细胞信号——均可改变肺神经内分泌细胞的修复能力。这些发现确定了一个调控巨噬细胞与上皮细胞通讯的 S100B–精氨酸酶-1 信号轴，并突出了 S100B 作为潜在肺修复治疗靶点的重要性。

### 第二部分 AI 大师评价

本研究揭示 S100B 通过与巨噬细胞间的信号互作，调控肺神经内分泌细胞在气道修复中的再生命运，阐明了肺上皮修复的关键分子轴。研究者利用小鼠模型，系统性分析了 S100B 活性变化对细胞分化与再生的影响，发现其与精氨酸酶-1 形成重要的信号联动机制。该工作创新性地将神经内分泌细胞与免疫细胞的网络联系到气道再生过程之中，为调控肺损伤修复提供了新方向。局限性在于尚需在人体体系中验证此信号通路的功能保守性与潜在临床可行性。

---

## 3. NutriSighT：用于预测机械通气患者肠内营养不足的可解释Transformer动态模型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408053)
**期刊：** Nature communications
**PMID：** 41408053
**DOI：** 10.1038/s41467-025-66200-1

### 第一部分 原文与翻译

**英文原标题：** NutriSighT: Interpretable Transformer Model for Dynamic Prediction of Underfeeding Enteral Nutrition in Mechanically Ventilated Patients.

> **英文摘要：**
> Achieving adequate enteral nutrition among mechanically ventilated patients is challenging, yet critical. We develop NutriSighT, a transformer model using learnable positional encodings to predict which patients would be underfed (receive less than 70% daily caloric requirements) between days 3-7 of mechanical ventilation and compared its performance against XGBoost. Using retrospective data from two ICU databases (3284 patients from AmsterdamUMCdb for development and 6456 from MIMIC-IV for external validation), we included adults mechanically ventilated for at least 72 h. NutriSighT achieved AUROC of 0.81 (95% CI: 0.81 - 0.82) and AUPRC of 0.70 (95% CI: 0.70 - 0.72) internally. External validation yielded AUROC of 0.76 (95% CI: 0.75 - 0.76) and an AUPRC of 0.70 (95% CI: 0.69 - 0.70). In comparison, XGBoost achieved AUROC of 0.58 (95% CI: 0.58 - 0.59) and AUPRC of 0.48 (95% CI: 0.46 - 0.50). This approach may help clinicians personalize nutritional therapy in critical care.

> **中文摘要：**
> 在机械通气患者中实现足够的肠内营养既具挑战性，又至关重要。我们开发了NutriSighT，这是一种使用可学习位置编码的Transformer模型，用于预测在机械通气的第3至第7天期间哪些患者将出现营养不足（即每日摄入热量低于70%的需求标准），并将其性能与XGBoost模型进行比较。研究使用来自两个重症监护数据库的回顾性数据（来自AmsterdamUMCdb的3284例患者用于模型开发，来自MIMIC-IV的6456例患者用于外部验证），纳入标准为成年且机械通气时间至少72小时。NutriSighT在内部验证中获得了0.81（95%置信区间：0.81–0.82）的AUROC和0.70（95%置信区间：0.70–0.72）的AUPRC。外部验证结果显示AUROC为0.76（95%置信区间：0.75–0.76），AUPRC为0.70（95%置信区间：0.69–0.70）。相比之下，XGBoost模型的AUROC为0.58（95%置信区间：0.58–0.59），AUPRC为0.48（95%置信区间：0.46–0.50）。该方法有望帮助临床医生在重症监护中实现个体化营养治疗。

### 第二部分 AI 大师评价

该研究旨在解决机械通气患者肠内营养不足预测的难题，通过引入可解释的Transformer模型NutriSighT，实现了对营养摄入不足风险的动态预测。作者基于双中心ICU数据库验证了模型的内外部性能，显示其预测能力明显优于传统机器学习方法XGBoost。研究突出了深度学习在临床营养管理中的潜力，并为精准个体化治疗提供了新思路。其局限在于主要基于回顾性数据，仍需前瞻性验证以支持临床应用。

---

## 4. AAK1 激活介导的铁转运驱动铁死亡的细胞过程

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407700)
**期刊：** Nature communications
**PMID：** 41407700
**DOI：** 10.1038/s41467-025-67523-9

### 第一部分 原文与翻译

**英文原标题：** AAK1 activation-mediated iron trafficking drives ferroptotic cell death.

> **英文摘要：**
> Ferrous iron is necessary for the occurrence of ferroptosis. The molecular mechanisms that maintain iron homeostasis within cells play a crucial role in the regulation of ferroptosis. However, how cells regulate iron uptake during ferroptosis remains unclear. Here, PKCβII is identified as a key kinase mediating transferrin receptor 1 (TFR1) endocytosis through phosphorylation and activation of AP2-associated protein kinase 1 (AAK1) during the ferroptotic process. Mechanistically, activated AAK1 phosphorylates AP2M1, which facilitates the recruitment of clathrin to mediate the endocytosis of TFR1, increasing the levels of both cellular total iron and ferrous iron and thereby promoting ferroptosis. The non-phosphorylatable mutation of AAK1 inhibits ferroptosis and consequently promotes breast tumor growth in vivo. In conclusion, we identify that the PKCβII-AAK1-AP2M1 pathway is a crucial mechanism for the regulation of cellular iron uptake during ferroptosis, which is correlated with the prognosis of breast cancer patients and presents a potential target for cancer therapy.

> **中文摘要：**
> 亚铁离子对于铁死亡的发生是必需的。维持细胞内铁稳态的分子机制在铁死亡的调控中起着关键作用。然而，细胞在铁死亡过程中如何调节铁的摄取尚不清楚。在此研究中，发现 PKCβII 是在铁死亡过程中通过磷酸化并激活 AP2 相关蛋白激酶 1（AAK1）来介导转铁蛋白受体 1（TFR1）内吞的关键激酶。从机制上看，活化的 AAK1 可磷酸化 AP2M1，促进网格蛋白的募集，从而介导 TFR1 的内吞，增加细胞总铁和亚铁的水平，从而促进铁死亡。不可磷酸化的 AAK1 突变可抑制铁死亡，进而在体内促进乳腺肿瘤的生长。总之，我们发现 PKCβII-AAK1-AP2M1 通路是铁死亡过程中调控细胞铁摄取的重要机制，与乳腺癌患者的预后密切相关，并可能成为潜在的肿瘤治疗靶点。

### 第二部分 AI 大师评价

该研究揭示了 PKCβII-AAK1-AP2M1 信号通路在铁死亡过程中调控细胞铁摄取的关键作用。通过分子与功能实验，作者阐明了 AAK1 激活如何促进 TFR1 内吞，从而提升细胞内铁水平并加速铁死亡。该发现将铁稳态的调控与肿瘤进展联系起来，为乳腺癌的预后评估和靶向治疗提供了新的思路。研究的创新性在于识别了铁死亡信号中的关键激酶级联，但其在不同肿瘤类型中的普适性仍有待进一步研究。

---

## 5. PARP1 介导的 ADP-核糖化全局重塑抑制甲型流感病毒感染

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407686)
**期刊：** Nature communications
**PMID：** 41407686
**DOI：** 10.1038/s41467-025-66136-6

### 第一部分 原文与翻译

**英文原标题：** Global remodeling of ADP-ribosylation by PARP1 suppresses influenza A virus infection.

> **英文摘要：**
> ADP-ribosylation is a highly dynamic and fully reversible post-translational modification performed by PARP enzymes that modulates protein function, abundance, localization, and turnover. Here we show that PARPs mount an antiviral response to influenza A virus infection causing a rapid and dramatic upregulation of global ADP-ribosylation that inhibits viral replication. Mass spectrometry analyzes define the global ADP-ribosylome during infection, creating an infection-specific profile with almost 4000 modification sites on ~1000 host proteins, as well as over 100 modification sites on viral proteins. Our data suggest that the global increase reflects a change in the form of ADP-ribosylation rather than modification of new targets. Functional assays demonstrate that modification of the viral replication machinery antagonizes its activity. We further show that the influenza A virus protein NS1 counteracts the anti-viral activity of PARPs and ADP-ribosylation, assigning a new activity to the primary viral antagonist of innate immunity. We identify PARP1 as the enzyme producing the majority of poly(ADP-ribose) present during infection. Influenza A virus replicates faster in cells lacking PARP1, linking PARP1 and ADP-ribosylation to the anti-viral phenotype. Together, these data establish ADP-ribosylation as an anti-viral innate immune-like response to viral infection antagonized by a previously unknown activity of NS1.

> **中文摘要：**
> ADP-核糖化是一种由 PARP 酶催化的高度动态且完全可逆的翻译后修饰，能够调节蛋白质的功能、丰度、定位及周转。我们在此表明，PARPs 在甲型流感病毒感染中启动抗病毒反应，导致全局 ADP-核糖化水平迅速且显著升高，从而抑制病毒复制。质谱分析揭示了感染过程中全局 ADP-核糖化组的构成，建立了感染特异性的修饰图谱，其中包含约 1000 个宿主蛋白的近 4000 个修饰位点，以及超过 100 个病毒蛋白的修饰位点。我们的数据表明，这种全局增加反映的并非新靶点的修饰，而是 ADP-核糖化形式的变化。功能实验显示，对病毒复制机器的修饰会拮抗其活性。我们进一步发现，甲型流感病毒蛋白 NS1 能抵消 PARPs 及 ADP-核糖化的抗病毒活性，从而赋予这一主要先天免疫拮抗因子新的功能。我们鉴定出 PARP1 是感染过程中产生大部分多(ADP-核糖)的酶。在缺乏 PARP1 的细胞中，甲型流感病毒复制更快，揭示了 PARP1 与 ADP-核糖化在抗病毒表型中的联系。总体而言，这些数据确立了 ADP-核糖化作为类似先天免疫反应的抗病毒机制，而该机制受到 NS1 一种此前未知活性的拮抗。

### 第二部分 AI 大师评价

本研究揭示了 PARP1 通过全局重塑 ADP-核糖化参与宿主针对甲型流感病毒的抗病毒防御机制。作者利用质谱学系统描绘了感染期间的 ADP-核糖化组学图谱，并确定 PARP1 是主要的多(ADP-核糖)合成酶。研究发现该修饰能抑制病毒复制并被 NS1 蛋白拮抗，从而揭示了 NS1 的新功能。这项工作在定义感染诱导的蛋白质翻译后修饰网络及其免疫调控意义方面具有重要创新，为抗病毒靶向调控提供了新思路，但仍需进一步探索其在不同病毒和宿主系统中的普适性。

---

## 6. 抗逆转录病毒治疗时代基于CD4计数和年龄的HIV感染者社区获得性肺炎与带状疱疹发病率：一项纵向队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406983)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41406983
**DOI：** 10.1093/cid/ciaf686

### 第一部分 原文与翻译

**英文原标题：** Incidence of community-acquired pneumonia and herpes zoster in people with HIV based on CD4-count and age in the current antiretroviral therapy era: a longitudinal cohort study.

> **英文摘要：**
> INTRODUCTION: People with HIV (PWH) using antiretroviral therapy (ART) remain at increased risk for infections such as community-acquired pneumonia (CAP) and herpes zoster (HZ), for which vaccinations are recommended. However, these recommendations do not consider the combined effects of age, CD4 count, and duration of ART on infection risk. We assessed how these factors influence CAP and HZ incidence to better tailor vaccination strategies.
> 
> METHODS: We used data from a nationwide cohort study including all PWH aged ≥18 years in care between 2010 and 2023. All documented CAP and HZ episodes were included, and incidence rates were calculated per 1000 person-years of follow-up (PYFU), stratified by age, CD4 count, and ART duration.
> 
> RESULTS: CAP and HZ incidence rates were highest in PWH with CD4 ≤200 cells/µL, ranging from 34-107/1000 PYFU for CAP and 9-63/1000 PYFU for HZ, depending on age. In those with CD4 ≥500 cells/µL and ≥1 year on ART, incidence rates ranged from 5-20/1000 PYFU for CAP and 4-5/1000 PYFU for HZ, depending on age.
> 
> CONCLUSION: Incidence rates are the highest in PWH with CD4 counts ≤200 cells/μL and/or not on ART, whereas PWH with CD4 counts ≥500 and ≥1 year on ART have a risk of CAP and HZ comparable to that of the general population. These findings support aligning vaccine recommendations for PWH on long-term suppressive ART with immune reconstitution with those for the general population, while HIV-specific vaccination strategies may remain most relevant for individuals with virological failure and/or poor immune reconstitution.

> **中文摘要：**
> 引言：接受抗逆转录病毒治疗（ART）的HIV感染者（PWH）仍然面临较高的感染风险，如社区获得性肺炎（CAP）和带状疱疹（HZ），针对这些感染建议进行疫苗接种。然而，这些接种建议并未考虑年龄、CD4计数及ART持续时间对感染风险的综合影响。本研究评估这些因素如何影响CAP与HZ的发病率，以更好地制定个体化的疫苗接种策略。
> 
> 方法：我们使用了一项全国性队列研究的数据，纳入2010年至2023年间接受照护的所有年龄≥18岁的HIV感染者。所有有记录的CAP和HZ事件均被纳入，发病率以每1000人年随访（PYFU）计算，并按年龄、CD4计数和ART持续时间分层分析。
> 
> 结果：CD4计数≤200个细胞/µL的HIV感染者其CAP和HZ的发生率最高，其中CAP为34–107/1000 PYFU，HZ为9–63/1000 PYFU，随年龄不同而变化。对于CD4计数≥500个细胞/µL且ART≥1年的个体，CAP的发病率为5–20/1000 PYFU，HZ的发病率为4–5/1000 PYFU，同样随年龄有所差异。
> 
> 结论：CD4计数≤200个细胞/μL及/或未接受ART的HIV感染者其发病率最高；而CD4计数≥500且ART≥1年的感染者，其CAP与HZ风险已接近普通人群。研究结果支持：对于长期抑制性ART且已实现免疫重建的HIV感染者，疫苗接种建议应与普通人群一致；而针对病毒学失败及/或免疫重建不足者，仍需保留特定的HIV专用疫苗接种策略。

### 第二部分 AI 大师评价

本研究利用全国性纵向队列数据，系统分析了HIV感染者在抗逆转录病毒治疗时代下，年龄、CD4计数及ART持续时间对社区获得性肺炎和带状疱疹发病率的影响。结果清晰地说明了免疫状态和治疗时间对感染风险的决定性作用。研究发现高CD4计数且长期ART的HIV感染者，其风险接近普通人群，为优化疫苗接种指南提供了实证依据。创新之处在于动态整合多维度免疫指标指导疫苗策略；局限性在于潜在的队列选择偏倚及未纳入其他合并免疫因素。

---

## 7. 靶向 TFAP2β 凝聚抑制食管鳞状细胞癌的发生发展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406964)
**期刊：** Cell
**PMID：** 41406964
**DOI：** 10.1016/j.cell.2025.11.019

### 第一部分 原文与翻译

**英文原标题：** Targeting TFAP2β condensation suppresses the development of esophageal squamous cell carcinoma.

> **英文摘要：**
> Exploring targeted therapies for esophageal squamous cell carcinoma (ESCC) remains challenging. Although investigating the roles and therapeutic applications of liquid-liquid phase separation (LLPS) is increasingly of interest, its relationship with ESCC remains unclear. After improving the assay for transposase-accessible chromatin using sequencing (ATAC-seq) protocol for limited-amount clinical samples, we unravel transcription factor AP-2 beta (TFAP2β) as a key downregulated transcription factor (TF) through combined chromatin accessibility and gene expression analyses with cancerous and paracancerous tissues from early-stage ESCC patients. TFAP2β undergoes condensation in the nucleus to bind the zinc finger protein 131 (ZNF131) promoter, thereby inhibiting ZNF131 expression and ESCC progression. The other two crucial downregulated TFs uncovered are incorporated into TFAP2β condensates to bind their corresponding target, suggesting that LLPS may be a hallmark of ESCC transcription. In addition, we obtained compound A6 that mediates intrinsically disordered region conformational changes to enhance TFAP2β condensation and specific ESCC suppression in cells, mice, and patient-derived organoids. Thus, we indicate an LLPS-mediated transcriptional mechanism and a potential therapeutic approach for ESCC.

> **中文摘要：**
> 探索针对食管鳞状细胞癌（ESCC）的靶向治疗仍然具有挑战性。尽管对液-液相分离（LLPS）的功能及其治疗应用的研究日益受到关注，但其与 ESCC 的关系仍不清楚。在改进了用于有限临床样本的转座酶可及染色质测序（ATAC-seq）实验方案后，本研究通过结合癌变与癌旁组织的染色质可及性和基因表达分析，揭示了转录因子 AP-2 β（TFAP2β）是关键的下调转录因子。TFAP2β 在细胞核内发生凝聚并结合锌指蛋白 131（ZNF131）的启动子，从而抑制 ZNF131 的表达并阻止 ESCC 的进展。研究还发现另外两个重要的下调转录因子被整合进 TFAP2β 凝聚体中，结合各自的靶基因位点，提示 LLPS 可能是 ESCC 转录调控的标志特征。此外，研究获得了能够介导无序结构区域构象变化、增强 TFAP2β 凝聚并在细胞、小鼠及来源于患者的类器官中特异性抑制 ESCC 的化合物 A6。因此，本研究揭示了一种由 LLPS 介导的转录调控机制及其潜在治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明液-液相分离在食管鳞状细胞癌发生发展中的作用及其潜在治疗靶点。作者通过改进 ATAC-seq 技术并结合转录组分析，发现 TFAP2β 作为关键下调转录因子在核内形成凝聚体，抑制 ZNF131 表达，从而抑制肿瘤进展。进一步证实 LLPS 现象可能是 ESCC 转录特征的重要标志，并发现化合物 A6 可增强 TFAP2β 凝聚以特异性抑癌。该研究创新性地揭示了 LLPS 介导的转录机制，为 ESCC 的靶向干预提供了新思路，但仍需进一步探讨其在临床应用中的安全性和长期效应。

---

## 8. 一种可口服生物利用的MrgprX1正向别构调节剂可减轻人源化小鼠中某些神经病理性疼痛相关行为。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406243)
**期刊：** Science translational medicine
**PMID：** 41406243
**DOI：** 10.1126/scitranslmed.adw9446

### 第一部分 原文与翻译

**英文原标题：** An orally bioavailable MrgprX1-positive allosteric modulator alleviates certain neuropathic pain-related behaviors in humanized mice.

> **英文摘要：**
> The human -related G protein-coupled receptor X1 (MrgprX1) represents a promising nonopioid analgesic target because of its selective expression in primary nociceptive sensory neurons. Positive allosteric modulators (PAMs) promote receptor signaling, depending on the availability of endogenous ligands, offering physiological selectivity over orthosteric agonists. We developed an orally bioavailable MrgprX1 PAM, 6-tert-butyl-5-(4-chlorophenyl)-4-(2-fluoro-6-(trifluoromethoxy)phenoxy)thieno[2,3-d]pyrimidine (BCFTP). BCFTP selectively potentiated the functional response of MrgprX1 in HEK293 cells, was metabolically stable, and demonstrated a favorable in vitro safety profile. BCFTP was orally bioavailable and distributed into the spinal cords of wild-type mice. BAM22, an endogenous ligand for MrgprX1, was up-regulated in the spinal cord after nerve injury in both wild-type and humanized MrgprX1 mice and was expressed in peptidergic and nonpeptidergic dorsal root ganglion neurons. Oral administration of BCFTP dose-dependently inhibited heat hyperalgesia and spontaneous pain-like behavior but not mechanical hypersensitivity after sciatic chronic constrictive injury (CCI) in MrgprX1 mice. BCFTP did not have analgesic effects in Mrgpr cluster knockout (Mrgpr) mice, indicating that the analgesic effects in MrgprX1 mice were MrgprX1 dependent. BCFTP enhanced BAM8-22-induced, MrgprX1-mediated reduction of C-fiber eEPSC amplitudes in spinal lamina II neurons, indicating inhibition of spinal nociceptive synaptic transmission. BCFTP did not induce tolerance or side effects, such as itch, sedation, and motor incoordination, and had no rewarding properties. The mRNAs encoding MrgprX1 and μ-opioid receptors were colocalized in human DRG neurons, and BCFTP synergistically enhanced morphine analgesia in CCI MrgprX1 mice. Our research suggests an approach for developing safer, orally bioavailable MrgprX1 PAM as a nonopioid therapy for neuropathic pain.

> **中文摘要：**
> 人源G蛋白偶联受体X1（MrgprX1）因其在初级伤害感受性感觉神经元中的选择性表达而被视为一种具有前景的非阿片类镇痛靶点。正向别构调节剂（PAM）通过依赖内源性配体的可用性来促进受体信号传导，相较正向激动剂具有更高的生理选择性。我们开发了一种可口服生物利用的MrgprX1 PAM，即6-叔丁基-5-(4-氯苯基)-4-(2-氟-6-(三氟甲氧基)苯氧基)噻吩并[2,3-d]嘧啶（BCFTP）。BCFTP在HEK293细胞中可选择性增强MrgprX1的功能反应，具有代谢稳定性，并显示出良好的体外安全性。BCFTP具有口服生物利用性，且可分布至野生型小鼠脊髓中。MrgprX1的内源性配体BAM22在野生型及人源化MrgprX1小鼠的神经损伤后脊髓中上调，并在含肽和非含肽的背根神经节神经元中表达。口服给予BCFTP可剂量依赖性地抑制MrgprX1小鼠坐骨神经慢性缩窄损伤（CCI）后的热性痛觉过敏和自发性疼痛样行为，但对机械性高敏反应无明显影响。BCFTP在Mrgpr簇敲除（Mrgpr）小鼠中未表现镇痛作用，表明其镇痛效应依赖于MrgprX1。BCFTP增强了由BAM8-22诱导的、MrgprX1介导的脊髓Ⅱ层神经元C纤维eEPSC幅度减少，提示其抑制了脊髓伤害性传入突触传递。BCFTP未引起耐受或诸如瘙痒、镇静及运动失调等副反应，也无奖赏特性。编码MrgprX1与μ-阿片受体的mRNA在人体背根神经节神经元中共定位，且BCFTP可协同增强CCI MrgprX1小鼠吗啡的镇痛效应。本研究提出了一种开发更安全、可口服生物利用的MrgprX1正向别构调节剂作为非阿片类神经病理性疼痛治疗策略的途径。

### 第二部分 AI 大师评价

本研究旨在探索MrgprX1受体作为非阿片类镇痛靶点的潜力，并开发一种可口服的正向别构调节剂BCFTP。研究利用细胞和人源化小鼠模型，验证了BCFTP在促进MrgprX1信号传导、改善神经病理性疼痛行为及协同增强吗啡镇痛方面的效应。结果显示BCFTP具有良好的代谢稳定性、安全性及无成瘾性，且镇痛作用特异依赖于MrgprX1受体。该研究为开发安全、高效且非阿片依赖的神经病理性疼痛治疗新策略提供了实验证据。但目前仍需进一步评估其长期疗效与临床可转化性。

---

## 9. 一种用于研究定植和血管损伤的体外人血管模型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406015)
**期刊：** eLife
**PMID：** 41406015
**DOI：** 10.7554/eLife.107813

### 第一部分 原文与翻译

**英文原标题：** An in vitro human vessel model to study  colonization and vascular damages.

> **英文摘要：**
> Systemic infections leading to sepsis are life-threatening conditions that remain difficult to treat, and the limitations of current experimental models hamper the development of innovative therapies. Animal models are constrained by species-specific differences, while 2D cell culture systems fail to capture the complex pathophysiology of infection. To overcome these limitations, we developed a laser photoablation-generated, three-dimensional microfluidic model of meningococcal vascular colonization, a human-specific bacterium that causes sepsis and meningitis. Laser photoablation-generated hydrogel engineering allows the reproduction of vascular networks that are major infection target sites, and this model provides the relevant microenvironment reproducing the physiological endothelial integrity and permeability in vitro. By comparing with a human-skin xenograft mouse model, we show that the model system not only replicates in vivo key features of the infection, but also enables quantitative assessment with a higher spatiotemporal resolution of bacterial microcolony growth, endothelial cytoskeleton rearrangement, vascular E-selectin expression, and neutrophil response upon infection. Our device thus provides a robust solution bridging the gap between animal and 2D cellular models, paving the way for a better understanding of disease progression and developing innovative therapeutics.

> **中文摘要：**
> 导致脓毒症的全身性感染是威胁生命的疾病，且仍然难以治疗，而当前实验模型的局限性阻碍了创新疗法的发展。动物模型受到物种特异性差异的限制，而二维细胞培养系统无法反映感染的复杂病理生理学。为克服这些限制，我们开发了一种由激光光消融生成的三维微流控模型，用于研究脑膜炎奈瑟菌在血管中的定植。这种细菌是引发脓毒症和脑膜炎的人特异性病原体。激光光消融生成的水凝胶工程可重建感染主要靶位的血管网络，该模型在体外提供了能重现生理性内皮完整性和通透性的相关微环境。通过与人皮肤异种移植小鼠模型的比较，我们证明该系统不仅可再现体内感染的关键特征，还可在更高时空分辨率下实现对细菌微菌落生长、内皮细胞骨架重排、血管E-选择素表达及感染时中性粒细胞反应的定量评估。因此，我们的装置为桥接动物模型与二维细胞模型之间的差距提供了一种稳健的解决方案，为深入理解疾病进展及开发创新疗法铺平了道路。

### 第二部分 AI 大师评价

本研究旨在建立并验证一种基于激光光消融的三维微流控人血管模型，以模拟人特异性感染的血管定植和损伤过程。该模型成功重建了体外的血管微环境，使研究者能够在高时空分辨率下动态观察细菌定植及宿主内皮反应。相比动物模型和二维培养体系，该方法在生理相关性与可量化程度上均显著提升。研究为感染与脓毒症的机制探索及新型抗感染策略开发提供了创新平台，但其复杂制备及体外系统的生理差异仍可能限制临床外推性。

---

## 10. 脓毒性休克患者应激性溃疡预防中组胺-2受体拮抗剂与质子泵抑制剂的比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405382)
**期刊：** Critical care medicine
**PMID：** 41405382
**DOI：** 10.1097/CCM.0000000000006996

### 第一部分 原文与翻译

**英文原标题：** Comparison of Histamine-2 Receptor Antagonists and Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Patients With Septic Shock.

> **英文摘要：**
> OBJECTIVES: To compare the effectiveness of histamine-2 receptor antagonists (H2RAs) vs. proton pump inhibitors (PPIs) for stress ulcer prophylaxis on the occurrence of upper gastrointestinal bleeding (UGIB) and other clinical outcomes in hospitalized patients with septic shock.
> 
> DESIGN: Retrospective, multicenter, propensity-weighted cohort study.
> 
> SETTING: Conducted across 220 geographically diverse community and teaching hospitals in the United States.
> 
> PATIENTS: Adult patients (age ≥ 18 yr) with septic shock who were initiated on either H2RAs or PPIs on the day of hospital admission.
> 
> INTERVENTIONS: H2RAs (famotidine) or PPIs (pantoprazole, omeprazole, esomeprazole, or lansoprazole).
> 
> MEASUREMENTS AND MAIN RESULTS: The primary outcome was the occurrence of UGIB during hospitalization. Secondary outcomes included in-hospital mortality, ventilator-associated pneumonia, Clostridioides difficile infection, and hospital length of stay. Propensity scores with inverse probability of treatment weighting (IPTW) were used to control for confounding. Among 15,102 patients (5,492 H2RA, 9,610 PPI), the mean age was 65.8 ± 14.9 years, 47.8% were female, and 58.1% received invasive mechanical ventilation during hospitalization. After IPTW adjustment, PPI use was associated with a lower occurrence of UGIB compared with H2RA (odds ratio [OR], 0.78; 95% CI, 0.64-0.96; p = 0.016). A sensitivity analysis comparing famotidine to pantoprazole confirmed this finding (OR, 0.80; 95% CI, 0.65-0.97; p = 0.025). No significant differences were observed in in-hospital mortality (OR, 0.98; 95% CI, 0.91-1.06; p = 0.691), ventilator-associated pneumonia (OR, 0.93; 95% CI, 0.83-1.04; p = 0.188), C. difficile infection (OR, 1.32; 95% CI, 0.82-2.13; p = 0.246), or hospital length of stay (incidence rate ratio, 1.01; 95% CI, 0.98-1.05; p = 0.417).
> 
> CONCLUSIONS: In this large, diverse cohort of U.S. hospitalized adults with septic shock, PPI use for stress ulcer prophylaxis was associated with a significantly lower occurrence of UGIB compared with H2RA, with no significant differences in mortality, ventilator-associated pneumonia, C. difficile infection, or hospital length of stay.

> **中文摘要：**
> 研究目的：比较组胺-2受体拮抗剂（H2RA）与质子泵抑制剂（PPI）在脓毒性休克住院患者应激性溃疡预防中的效果，主要关注上消化道出血（UGIB）及其他临床结局的发生情况。
> 
> 研究设计：回顾性、多中心、倾向性加权队列研究。
> 
> 研究场所：在美国220家地理分布广泛的社区医院及教学医院开展。
> 
> 研究对象：入院当天开始使用H2RA或PPI的成年脓毒性休克患者（年龄≥18岁）。
> 
> 干预措施：H2RA（法莫替丁）或PPI（泮托拉唑、奥美拉唑、艾司奥美拉唑或兰索拉唑）。
> 
> 测量与主要结果：主要结局为住院期间UGIB的发生。次要结局包括院内死亡率、呼吸机相关性肺炎、艰难梭菌感染及住院时间。采用逆概率加权（IPTW）的倾向评分以控制混杂因素。共纳入15,102例患者（H2RA组5,492例，PPI组9,610例），平均年龄65.8±14.9岁，女性占47.8%，58.1%于住院期间接受了有创机械通气。经IPTW调整后，PPI相较H2RA与UGIB的发生率更低相关（比值比[OR] 0.78；95%置信区间[CI] 0.64–0.96；p=0.016）。在法莫替丁与泮托拉唑的敏感性分析中得出一致结论（OR 0.80；95% CI 0.65–0.97；p=0.025）。在院内死亡率（OR 0.98；95% CI 0.91–1.06；p=0.691）、呼吸机相关性肺炎（OR 0.93；95% CI 0.83–1.04；p=0.188）、艰难梭菌感染（OR 1.32；95% CI 0.82–2.13；p=0.246）及住院时间（发生率比1.01；95% CI 0.98–1.05；p=0.417）方面未发现显著差异。
> 
> 研究结论：在美国大量、异质性的脓毒性休克成人住院患者队列中，与H2RA相比，PPI用于应激性溃疡预防显著降低了UGIB的发生率，但在死亡率、呼吸机相关性肺炎、艰难梭菌感染或住院时间方面无显著差异。

### 第二部分 AI 大师评价

本研究基于大型多中心回顾性数据，通过倾向评分加权方法，比较了H2RA与PPI在脓毒性休克患者应激性溃疡预防中的效益差异。结果显示，PPI明显降低了上消化道出血风险，而对死亡率、院内感染及住院时间无显著影响。该研究样本量大、设计严谨，增强了结果的可靠性。然而，回顾性设计和潜在未控制混杂因素仍可能影响因果推断。整体上，研究为重症感染患者应激性溃疡预防策略提供了重要证据。

---

## 11. 危重症患者急性肾损伤、谵妄及预后之间关联的系统综述与Meta分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405369)
**期刊：** Critical care medicine
**PMID：** 41405369
**DOI：** 10.1097/CCM.0000000000006997

### 第一部分 原文与翻译

**英文原标题：** Association Between Acute Kidney Injury, Delirium, and Outcomes in Patients With Critical Illness: A Systematic Review and Meta-Analysis.

> **英文摘要：**
> OBJECTIVES: Acute kidney injury (AKI) and delirium are common complications of critical illness. However, relatively few studies have evaluated their relationship. We conducted a systematic synthesis and meta-analysis of existing evidence to clarify this association in critically ill patients.
> 
> DATA SOURCES: A comprehensive search was conducted across MEDLINE, Embase, CINAHL, Scopus, Web of Science, and Cochrane Library for publications reporting both AKI and delirium in ICUs patients from January 2000 to January 2025.
> 
> STUDY SELECTION: AKI was defined according to serum creatinine or urine output criteria based on the contemporary definitions used in the individual studies. The primary outcome was the proportion of critically ill patients with AKI who developed delirium. Secondary outcomes included mortality and health service utilization.
> 
> DATA EXTRACTION: Pooled meta-analyses were summarized as effect sizes in proportions, risk ratios (RRs), odds ratios, or weighted mean differences (WMDs) using a random-effects model. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation approach.
> 
> DATA SYNTHESIS: Eighteen observational studies comprising 158,694 patients were included. Overall study quality was moderate. The pooled proportion of delirium among patients with AKI was 32% (95% CI, 18-47%). Delirium was associated with higher mortality (RR, 2.36; 95% CI, 1.61-3.47; moderate certainty), greater renal replacement therapy use (RR, 3.12; 95% CI, 1.89-5.15; moderate certainty), longer ICU stays (WMD, 3.54 d; 95% CI, 1.20-5.87 d; moderate certainty), and longer hospital stays (WMD, 4.78 d; 95% CI, 3.48-6.09 d; moderate certainty) compared with patients with AKI not experiencing delirium.
> 
> CONCLUSIONS: Delirium is common among critically ill patients with AKI and is associated with worse outcomes and greater health resource use.

> **中文摘要：**
> 研究目的：急性肾损伤（AKI）和谵妄是危重症常见的并发症。然而，关于两者关系的研究相对较少。本研究通过对现有证据的系统整合与Meta分析，旨在阐明危重症患者中AKI与谵妄的关联。
> 
> 数据来源：研究团队在MEDLINE、Embase、CINAHL、Scopus、Web of Science及Cochrane Library中系统检索了2000年1月至2025年1月间发表的，报告重症监护病房（ICU）患者中AKI与谵妄情况的文献。
> 
> 研究选择：AKI的定义基于各原始研究采用的当代标准，根据血清肌酐或尿量判定。主要结局为在危重症患者中，AKI患者发生谵妄的比例；次要结局包括死亡率及卫生服务资源利用情况。
> 
> 数据提取：采用随机效应模型对Meta分析进行汇总，结果以比例、风险比（RR）、比值比（OR）或加权平均差（WMD）等效应量形式呈现。证据确定性依据GRADE（推荐分级、评估与开发）方法进行评估。
> 
> 数据合成：共纳入18项观察性研究，合计158,694名患者。总体研究质量为中等。AKI患者中谵妄的汇总发生率为32%（95%置信区间，18–47%）。与未发生谵妄的AKI患者相比，谵妄的发生与更高的死亡率（RR 2.36；95% CI，1.61–3.47；中等确定性）、更频繁的肾脏替代治疗使用（RR 3.12；95% CI，1.89–5.15；中等确定性）、更长的ICU住院时间（WMD 3.54天；95% CI，1.20–5.87天；中等确定性）及更长的住院时间（WMD 4.78天；95% CI，3.48–6.09天；中等确定性）相关。
> 
> 结论：谵妄在危重症伴有AKI的患者中十分常见，并与不良预后及更高的医疗资源消耗显著相关。

### 第二部分 AI 大师评价

本系统综述与Meta分析旨在明确危重症患者中急性肾损伤与谵妄的关系。研究通过多数据库系统检索并汇总18项观察性研究，发现AKI患者中谵妄发生率高达32%，并显著增加死亡风险及延长住院时间。该研究的优势在于样本量大并采用GRADE标准评估证据质量，但局限于纳入研究均为观察性设计，异质性较高。总体而言，本研究为临床识别和管理危重症患者的谵妄风险提供了重要循证依据。

---

## 12. 通过 P116 靶向肝脏和动脉粥样硬化病灶的肺炎支原体必需脂质来源研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402265)
**期刊：** Nature communications
**PMID：** 41402265
**DOI：** 10.1038/s41467-025-66129-5

### 第一部分 原文与翻译

**英文原标题：** Sources of essential lipids for Mycoplasma pneumoniae via P116 to target liver and atherosclerotic lesions.

> **英文摘要：**
> Mycoplasma pneumoniae (MPN) is a bacterial pathogen that primarily causes atypical pneumonia. It cannot synthesize certain essential lipids and therefore relies on the host for their acquisition to survive. MPN has been detected in increased amounts within ruptured atherosclerotic plaques. In this work, we show that the protein P116 facilitates cholesterol acquisition from LDL, HDL and various cell types. Targeting P116's C-terminal domain with a monoclonal antibody inhibits cholesterol acquisition and bacterial growth in vitro. Phase contrast epifluorescence microscopy of human arteries reveals that this antibody blocks MPN binding to atherosclerotic lesions ex vivo. Additionally, an MPN chassis injected into hyperlipidemic female mice localizes to the liver and atherosclerotic plaques. Here, we report that P116 plays a role in extracting essential lipids from lipoproteins and host cells and regulates MPN localization to atheromatous plaques. The study highlights MPN's potential as a tool for targeting atherosclerotic lesions and fatty liver.

> **中文摘要：**
> 肺炎支原体（Mycoplasma pneumoniae，MPN）是一种主要引起非典型肺炎的细菌病原体。它无法合成某些必需脂质，因此依赖宿主获取这些成分以维持生存。在破裂的动脉粥样硬化斑块中检测到 MPN 含量增高。在本研究中，我们发现蛋白质 P116 可促进从低密度脂蛋白（LDL）、高密度脂蛋白（HDL）及多种细胞类型中获得胆固醇。使用单克隆抗体靶向 P116 的 C 端结构域可在体外抑制胆固醇的摄取及细菌的生长。人动脉的相差表面荧光显微镜观察显示，该抗体可在离体条件下阻断 MPN 与动脉粥样硬化病灶的结合。此外，将 MPN 骨架注射入高脂血症雌性小鼠后，发现其定位于肝脏和动脉粥样硬化斑块处。本研究报道，P116 参与从脂蛋白和宿主细胞中提取必需脂质，并调控 MPN 定位至粥样斑块。该研究强调了 MPN 作为靶向动脉粥样硬化病灶及脂肪肝的潜在工具价值。

### 第二部分 AI 大师评价

该研究揭示了肺炎支原体通过表面蛋白 P116 从宿主脂蛋白和细胞中获取胆固醇的机制，并指出其可定位至动脉粥样硬化斑块与肝组织。研究采用单克隆抗体干预和显微成像技术，系统验证了 P116 在脂质吸收及组织靶向中的关键作用。结果不仅深化了对支原体代谢与宿主互作的认识，也提出其作为动脉粥样硬化与脂肪肝靶向载体的潜在应用。创新性强，但仍需进一步验证其在体内长期安全性及特异性。

---

## 13. 将宿主生物标志物与大型语言模型整合用于下呼吸道感染的诊断

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402257)
**期刊：** Nature communications
**PMID：** 41402257
**DOI：** 10.1038/s41467-025-66218-5

### 第一部分 原文与翻译

**英文原标题：** Integrating a host biomarker with a large language model for diagnosis of lower respiratory tract infection.

> **英文摘要：**
> Lower respiratory tract infections (LRTI) are a leading cause of mortality and are challenging to diagnose in critically ill patients, as non-infectious causes of respiratory failure can present with similar clinical features. We develop an LRTI diagnostic method combining the pulmonary transcriptomic biomarker FABP4 with electronic medical record text assessment using the large language model Generative Pre-trained Transformer 4. In a cohort of critically ill adults, a combined classifier incorporating FABP4 expression and large language model electronic medical record analysis achieves an area under the receiver operating characteristic curve (AUC) of 0.93 ± 0.08 and an accuracy of 84%, outperforming FABP4 expression alone (0.84 ± 0.11) and large language model-based analysis alone (0.83 ± 0.07). By comparison, the medical team admission diagnosis has an accuracy of 72%. In an independent validation cohort, the combined classifier yields an AUC of 0.98 ± 0.04 and accuracy of 96%. This study suggests that integrating a host biomarker with large language model analysis can improve LRTI diagnosis in critically ill adults.

> **中文摘要：**
> 下呼吸道感染（LRTI）是导致死亡的主要原因之一，在危重患者中诊断具有挑战性，因为非感染性呼吸衰竭也可能呈现出相似的临床表现。我们开发了一种LRTI诊断方法，将肺部转录组生物标志物FABP4与基于大型语言模型（生成式预训练变换器4，GPT-4）的电子病历文本评估相结合。在危重成人队列中，结合FABP4表达与大型语言模型电子病历分析的分类器获得了接收者工作特征曲线下面积（AUC）为0.93 ± 0.08、准确率为84%的结果，优于仅使用FABP4表达（0.84 ± 0.11）或仅使用大型语言模型分析（0.83 ± 0.07）。相比之下，医疗团队的入院诊断准确率为72%。在独立验证队列中，该联合分类器的AUC为0.98 ± 0.04，准确率为96%。本研究表明，将宿主生物标志物与大型语言模型分析相结合，可提高危重成人LRTI的诊断准确性。

### 第二部分 AI 大师评价

本研究创新性地结合宿主转录组生物标志物FABP4与大型语言模型文本分析，用于危重患者下呼吸道感染的诊断。联合模型显著优于单一生物标志物或语言模型，表现出更高的AUC和准确率，尤其在独立验证队列中仍具卓越表现。该方法展示了人工智能与分子生物学协同提升临床诊断性能的潜力，但其推广仍需在多中心验证和不同疾病谱中进一步评估。

---

## 14. 一种广谱中和抗体通过抑制gB介导的膜融合赋予α疱疹病毒属间交叉保护作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402251)
**期刊：** Nature communications
**PMID：** 41402251
**DOI：** 10.1038/s41467-025-66099-8

### 第一部分 原文与翻译

**英文原标题：** A broadly neutralizing antibody confers cross-genus protection against alphaherpesviruses by inhibiting gB-mediated membrane fusion.

> **英文摘要：**
> The global prevalence and disease burden of alphaherpesviruses infections, including human-infecting viruses such as HSV-1, HSV-2, and VZV, as well as animal-infecting viruses like PRV, BHV, CHV, and FHV, highlight the unmet need for more effective and universal antiviral strategies. However, there has been no significant progress in developing broad-spectrum interventions against herpesvirus. Here we report the identification of a broadly neutralizing antibody against alphaherpesviruses, 16F9, which targets the glycoprotein B (gB) of alphaherpesviruses and offers cross-protection against multiple viruses such as HSV-1, HSV-2, and PRV in mice. 16F9 demonstrated robust therapeutic efficacy in various female mouse models of herpesvirus diseases including PRV-induced viral encephalitis, HSV-1-induced viral encephalitis, viral keratitis, cutaneous herpes, and neonatal herpesvirus infections. High-resolution cryo-electron microscopy structures revealed that 16F9 binds a conserved site of vulnerability on Domain I of gB. The binding of 16F9 disrupts the interaction between pre-gB and gHgL complex, thereby preventing viral membrane fusion and blocking viral infection. This study provides a foundation for advancing antiviral strategies and underscores the potential of gB-targeted interventions for combating herpesvirus infections.

> **中文摘要：**
> α疱疹病毒感染（包括感染人类的HSV-1、HSV-2和VZV，以及感染动物的PRV、BHV、CHV和FHV）的全球流行及其疾病负担，凸显了开发更有效且通用的抗病毒策略的紧迫需求。然而，目前在研发针对疱疹病毒的广谱干预措施方面尚无显著进展。本研究报道了一种针对α疱疹病毒的广谱中和抗体16F9。该抗体靶向α疱疹病毒的糖蛋白B（gB），在小鼠中可对包括HSV-1、HSV-2和PRV在内的多种病毒提供交叉保护。16F9在多种雌性小鼠疱疹病毒疾病模型中表现出强效的治疗作用，这些模型包括PRV诱导的病毒性脑炎、HSV-1诱导的病毒性脑炎、病毒性角膜炎、皮肤疱疹以及新生鼠疱疹病毒感染。高分辨率冷冻电子显微镜结构显示，16F9结合于gB的结构域I上一个保守的易感位点。16F9的结合破坏了前体gB与gHgL复合物之间的相互作用，从而阻止病毒膜融合并阻断病毒感染。本研究为推进抗病毒策略提供了基础，并强调了以gB为靶点的干预手段在抗击疱疹病毒感染中的潜力。

### 第二部分 AI 大师评价

该研究针对长期缺乏广谱疗法的疱疹病毒感染问题，鉴定出一种可跨属中和多种α疱疹病毒的抗体16F9。研究通过动物模型验证了其在脑炎、角膜炎及皮肤疱疹等多种疾病中的治疗潜能，并结合冷冻电镜技术阐明了其作用机制——抑制gB介导的膜融合。该工作在病毒结构与免疫干预结合方面具有显著创新性，为gB靶向抗病毒药物的开发奠定了重要基础。局限性在于现阶段验证主要来自小鼠模型，尚需进一步评估其在人类中的有效性与安全性。

---

## 15. 生物标志物与急性肾损伤及肾脏替代治疗启动的预测：梦中之梦。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400678)
**期刊：** Intensive care medicine
**PMID：** 41400678
**DOI：** 10.1007/s00134-025-08254-9

### 第一部分 原文与翻译

**英文原标题：** Biomarkers and the prediction of acute kidney injury and renal replacement therapy initiation: a dream within a dream.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文通过探讨生物标志物在预测急性肾损伤（AKI）及肾脏替代治疗启动方面的潜力，揭示了该领域研究的复杂性与挑战。从标题的隐喻可以看出，作者或许强调了预测模型与临床现实之间的差距。文章可能综述了当前关键生物标志物的表现及其在重症监护中的应用局限。总体而言，该研究提示未来要实现精准预测仍需更多大规模验证研究与多维数据整合。

---

## 16. 重症监护病房获得性肌无力研究的新纪元——从发病机制到有意义的康复。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400676)
**期刊：** Intensive care medicine
**PMID：** 41400676
**DOI：** 10.1007/s00134-025-08246-9

### 第一部分 原文与翻译

**英文原标题：** A new era for ICU-acquired weakness research-from mechanisms to meaningful recovery.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文标题表明该研究聚焦于重症监护病房获得性肌无力（ICU-AW）领域的发展前沿，强调从分子和细胞机制层面到患者功能性康复的全链条研究转变。虽然未提供摘要，但可推测其旨在推动基础研究与临床康复之间的整合，强调恢复质量与长期预后。该方向的创新性在于连接机制研究与临床实践之间的“最后一公里”，为ICU幸存者的功能恢复提供新见解。然而，缺乏具体数据和方法说明可能限制对其实证价值的深度评估。

---

## 17. 肾脏替代治疗的趋势：向保守管理演进的十年变迁

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400675)
**期刊：** Intensive care medicine
**PMID：** 41400675
**DOI：** 10.1007/s00134-025-08247-8

### 第一部分 原文与翻译

**英文原标题：** Trends in renal replacement therapy: a decade of evolution toward conservative management.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究聚焦近十年来肾脏替代治疗（RRT）在重症医学领域中的变革，特别是向更加保守管理策略转变的趋势。虽然未提供摘要，但从标题推测，作者可能基于多中心临床数据或宏观流行病学分析，对RRT的启动标准、模式选择及预后演变进行了总结。该研究的创新性在于揭示医疗实践中由积极干预向个体化、谨慎干预的转向趋势。其局限性可能在于不同地区临床路径差异对结果的影响仍需进一步明确。

---

## 18. 败血症死亡率趋势：一箭双雕之策？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400674)
**期刊：** Intensive care medicine
**PMID：** 41400674
**DOI：** 10.1007/s00134-025-08245-w

### 第一部分 原文与翻译

**英文原标题：** Mortality trends in sepsis… or how to kill two birds with one stone?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该文章标题暗示其核心议题在于探讨败血症相关死亡率的变化趋势，并可能从中提出兼顾多重目标的研究视角。尽管未提供摘要，但从标题推测，作者或在分析流行病学数据的同时，反思临床管理策略对整体病死率的影响。此类研究有助于揭示重症监护领域治疗改进与公共卫生成果之间的关联。然而，由于缺乏具体方法和结果信息，研究的创新性与适用范围尚待进一步评估。

---

## 19. 早期抗生素使用会损害成年期的MAIT细胞介导免疫

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400657)
**期刊：** The Journal of experimental medicine
**PMID：** 41400657
**DOI：** 10.1084/jem.20241287

### 第一部分 原文与翻译

**英文原标题：** Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood.

> **英文摘要：**
> Mucosal-associated invariant T (MAIT) cells are predominantly located in barrier tissues where they rapidly respond to pathogens and commensals by recognizing microbial derivatives of riboflavin synthesis. Early-life exposure to these metabolites imprints the abundance of MAIT cells within tissues, so we hypothesized that antibiotic use during this period may abrogate their development. We identified antibiotics that deplete riboflavin-synthesizing commensals and revealed an early period of susceptibility during which antibiotic administration impaired MAIT cell development. The reduction in MAIT cell abundance rendered mice more susceptible to pneumonia, while MAIT cell-deficient mice were unaffected by early-life antibiotics. Concomitant administration of a riboflavin-synthesizing commensal during antibiotic treatment was sufficient to restore MAIT cell development and immunity. Our work demonstrates that transient depletion of riboflavin-synthesizing commensals in early life can adversely affect responses to subsequent infections.

> **中文摘要：**
> 黏膜相关不变T（MAIT）细胞主要分布于屏障组织中，在这些部位它们通过识别源自核黄素合成途径的微生物代谢物，能够迅速对病原体和共生菌做出反应。早期生命阶段对这些代谢物的暴露会在组织内“铭刻”MAIT细胞的丰度，因此我们假设，此阶段使用抗生素可能会阻断其发育。我们鉴定了可耗竭核黄素合成共生菌的抗生素，并揭示了一个早期易感时期，在此期间给予抗生素会损害MAIT细胞的发育。MAIT细胞丰度的降低使小鼠更易发生肺炎，而MAIT细胞缺陷小鼠在早期使用抗生素后则未受影响。在抗生素治疗期间同步给予一种核黄素合成共生菌即可恢复MAIT细胞的发育和免疫功能。我们的研究表明，早期生命阶段核黄素合成共生菌的短暂缺失可能对其后感染的免疫反应产生不利影响。

### 第二部分 AI 大师评价

该研究聚焦于早期抗生素暴露对MAIT细胞发育及成年期免疫功能的影响，揭示了核黄素合成共生菌对MAIT细胞免疫记忆塑造的重要性。作者通过动物模型系统性地鉴定了抗生素的易感窗口期，并证实补充核黄素合成共生菌可逆转免疫损伤。该工作创新性在于揭示抗生素通过改变微生物代谢网络间接损害宿主免疫的机制，为儿童用药安全及微生物组干预提供了新思路。但研究主要基于小鼠模型，未来亟需在人体中验证其临床意义。

---

## 20. 应用纳米孔测序技术评估糖尿病足骨髓炎的微生物优势可预测手术治疗的良好反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400382)
**期刊：** The Journal of infectious diseases
**PMID：** 41400382
**DOI：** 10.1093/infdis/jiaf617

### 第一部分 原文与翻译

**英文原标题：** Microbial Dominance in Diabetic Foot Osteomyelitis using Nanopore Sequencing Techniques Predicts Positive Response to Surgical Intervention.

> **英文摘要：**
> BACKGROUND: Existing tools to predict successful response to surgery for the treatment of diabetic foot osteomyelitis are lacking. Recent studies in non-bone infections have revealed that nanopore sequencing can provide real-time metagenomic identification of pathogens. In a cohort of patients with diabetic foot osteomyelitis, we tested the feasibility of generating interpretable metagenomic data from surgically-acquired osseous tissue, and compared bacterial community features (pathogen dominance) with clinical outcomes (resolution of infection). We hypothesized that nanopore-generated microbial data can be feasibly generated from surgically-acquired bone, aligns with conventional culture results, and is predictive of clinical response.
> 
> METHODS: We performed a pilot feasibility study of ten consecutive patients hospitalized with diabetic foot osteomyelitis who underwent surgery for osteomyelitis. We performed metagenomic sequencing of surgical bone samples using the MinION (Oxford Nanopore). Our primary metagenomic index was community dominance (relative abundance of most abundant species). Our primary clinical endpoint was clinical response to surgery, adjudicated at one year.
> 
> RESULTS: We successfully generated interpretable metagenomic data from all (10/10) specimens, including two specimens with negative culture growth. Among culture-positive specimens, the culture-identified pathogen was either the first or second most abundant organism in all cases. Patients with favorable clinical response exhibited greater pathogen dominance than patients with unfavorable response (p=0.002).
> 
> CONCLUSIONS: In patients with surgically treated osteomyelitis, nanopore sequencing can generate interpretable metagenomic data from bone specimens that is culture-concordant and associated with clinical response. These findings support the feasibility and plausibility of using real-time metagenomic sequencing to improve the clinical management of osteomyelitis.

> **中文摘要：**
> 背景：目前缺乏可用于预测糖尿病足骨髓炎手术治疗成功反应的工具。近期在非骨感染研究中发现，纳米孔测序技术可实现病原体的实时宏基因组学鉴定。在一项糖尿病足骨髓炎患者队列研究中，我们评估了从手术获取的骨组织中生成可解释的宏基因组数据的可行性，并将细菌群落特征（病原体优势度）与临床结局（感染缓解）进行比较。我们假设，利用纳米孔技术生成的微生物数据可从手术所得骨组织中可行地获得，与传统培养结果一致，并可预测临床反应。
> 
> 方法：我们对连续收治并接受骨髓炎手术治疗的10例糖尿病足骨髓炎住院患者进行了初步可行性研究。利用MinION（牛津纳米孔技术）对手术骨标本进行宏基因组测序。主要的宏基因组学指标为群落优势度（最丰富物种的相对丰度），主要的临床终点为术后一年的临床反应。
> 
> 结果：我们在所有（10/10）标本中成功生成了可解释的宏基因组数据，包括两例培养阴性的标本。在培养阳性标本中，培养鉴定的病原体在所有病例中均为最优势或次优势的微生物。临床反应良好的患者表现出较差反应患者更高的病原体优势度（p=0.002）。
> 
> 结论：在接受手术治疗的骨髓炎患者中，纳米孔测序可从骨标本中生成与培养结果一致且可解释的宏基因组数据，并与临床反应相关。研究结果支持采用实时宏基因组测序以改善骨髓炎临床管理的可行性和合理性。

### 第二部分 AI 大师评价

本研究探索了利用纳米孔测序技术在糖尿病足骨髓炎中的微生物群落结构特征与手术疗效之间的关系。通过分析来自手术骨组织的宏基因组数据，作者发现病原体的主导性可与临床反应显著相关。研究创新地展示了实时宏基因组学技术在骨组织样本中的可行性，并为预测术后感染控制提供了潜在生物标志物。然而，研究样本量较小，仍需在更大规模队列中验证其预测价值和临床实用性。

---

## 21. 一种靶向肺泡巨噬细胞的环丙沙星高分子前药可改善小鼠肺炎模型的生存率。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400360)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41400360
**DOI：** 10.1128/aac.00363-25

### 第一部分 原文与翻译

**英文原标题：** An alveolar macrophage-targeted ciprofloxacin polymeric prodrug improves survival in a murine model of  pneumonia.

> **英文摘要：**
> is a leading cause of both hospital- and community-acquired pneumonia. Nanomaterials have the potential to deliver antibiotics directly to sites of infection with improved pharmacokinetics and to avoid development of antimicrobial resistance. We previously demonstrated the use of alveolar macrophage (AM)-targeted polymeric prodrugs to prevent pneumonia in murine models caused by the facultative intracellular pathogens  and . These fully synthetic mannose-tagged polymers engage with AM mannose receptors, permitting uptake and triggering intracellular ciprofloxacin release. Here we show that the AMs can also serve as a reservoir for releasing antibiotics to treat infections caused by a primarily extracellular bacterium. Aerosolized ciprofloxacin polymeric prodrugs significantly improved survival in a murine model of  pneumonia, reduced lung bacterial burden, lessened extent of lung injury, and prevented excessive neutrophilic inflammation.

> **中文摘要：**
> 是一种导致医院获得性和社区获得性肺炎的主要病因。纳米材料具有将抗生素直接递送至感染部位、改善药代动力学特性并减少耐药性发展的潜力。我们此前已证明，靶向肺泡巨噬细胞（AM）的高分子前药可在由兼性胞内致病菌引起的小鼠肺炎模型中发挥预防作用。这些完全合成的甘露糖标记聚合物能够结合AM表面的甘露糖受体，从而促进其摄取并触发细胞内环丙沙星的释放。在本研究中，我们进一步表明，AM还可作为抗生素释放的储库，用于治疗由主要胞外细菌引起的感染。经雾化吸入的环丙沙星高分子前药显著提高了小鼠肺炎模型的生存率，降低了肺部细菌负荷，减轻了肺组织损伤程度，并防止了过度的中性粒细胞炎症反应。

### 第二部分 AI 大师评价

本研究旨在开发并验证一种靶向肺泡巨噬细胞的环丙沙星高分子前药以治疗肺炎。通过纳米聚合物载体与甘露糖受体的特异性结合，实现药物在巨噬细胞内靶向释放和二次抗菌效应。动物实验表明，这种制剂能有效改善生存率、降低肺部细菌负荷并减轻炎症损伤，突显其在抗生素递送和耐药控制方面的创新潜力。但未来仍需进一步评估其长期安全性及在人类中的转化效果。

---

## 22. 顺序器官功能衰竭评估（SOFA）-2 评分的开发与验证

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41159833)
**期刊：** JAMA
**PMID：** 41159833
**DOI：** 10.1001/jama.2025.20516

### 第一部分 原文与翻译

**英文原标题：** Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score.

> **英文摘要：**
> IMPORTANCE: Acute dysfunction of vital organs is the hallmark of critical illness. The Sequential Organ Failure Assessment (SOFA) score, the most widely adopted approach to describe organ dysfunction, has not been updated in 30 years and therefore may not appropriately capture current clinical practice and outcomes.
> 
> OBJECTIVES: To inform the data-driven component of an updated score (SOFA-2) in varied geographical and resource settings (stages 6-8) after expert input via a modified Delphi process (stages 1-5).
> 
> DESIGN, SETTING, AND PARTICIPANTS: A federated analysis was performed on data collected from adult patients admitted to 1319 intensive care units (ICUs) in 9 countries (Australia, Austria, Brazil, France, Italy, Japan, Nepal, New Zealand, United States) between 2014 and 2023. Four representative multicenter cohorts containing data from 2 098 356 patients were used for data-driven score development and internal validation. External validation was performed on 6 cohorts containing data from 1 241 114 patients.
> 
> MAIN OUTCOMES AND MEASURES: Content validity for organ dysfunction identified through the modified Delphi process should be reflected by predictive validity using the area under the receiver operating characteristic (AUROC) curve of the score measured on the first ICU day (higher scores indicate worse organ dysfunction).
> 
> RESULTS: Of 3.34 million patient encounters, 270 108 (8.1%) died in the ICU (range, 4.5% to 20.5% across the 10 cohorts). SOFA-2 modified the 6 organ systems of the original SOFA score (brain, respiratory, cardiovascular, liver, kidney, hemostasis), including new variables and revised thresholds that better describe the organ dysfunction distribution from 0 to 4 points and their associated mortality (SOFA-2 AUROC, 0.79; 95% CI, 0.76-0.81; SOFA-1 AUROC, 0.77; 95% CI, 0.74-0.81). Evaluation of sequential SOFA-2 data from ICU day 1 to day 7 maintained its predictive validity. Insufficient data and lack of content validity precluded incorporation of gastrointestinal and immune dysfunction scores into SOFA-2.
> 
> CONCLUSIONS AND RELEVANCE: The SOFA-2 score, updated to include contemporary organ support treatments and new score thresholds, describes organ dysfunction in a large, geographically and socioeconomically diverse population of critically ill adults.

> **中文摘要：**
> 重要性：急性重要器官功能障碍是重症疾病的标志。顺序器官功能衰竭评估（SOFA）评分是描述器官功能障碍最广泛采用的方法，但在过去30年中未曾更新，因此可能无法准确反映当今的临床实践和预后结果。
> 
> 研究目的：在经过修订的Delphi专家共识流程（第1至第5阶段）后，为在不同地理及资源环境（第6至第8阶段）中更新的评分系统（SOFA-2）的数据驱动组成部分提供依据。
> 
> 研究设计、环境与参与者：本研究在2014年至2023年间，针对来自9个国家（澳大利亚、奥地利、巴西、法国、意大利、日本、尼泊尔、新西兰、美国）1319家重症监护病房（ICU）的成人患者数据进行联合分析。四个具有代表性的多中心队列（共2,098,356名患者）用于数据驱动的评分开发与内部验证；外部验证在6个队列（共1,241,114名患者）上进行。
> 
> 主要结局与测量：通过修订Delphi过程确定的器官功能障碍的内容效度应当通过评分在ICU入院首日计算的受试者工作特征曲线下面积（AUROC）来体现其预测效度（分值越高表示器官功能障碍越严重）。
> 
> 结果：在334万例患者入院记录中，共有270,108例（8.1%）在ICU死亡（10个队列的范围为4.5%至20.5%）。SOFA-2对原SOFA评分的6个器官系统（脑、呼吸、循环、肝脏、肾脏、凝血）进行了修改，纳入了新变量并调整了评分阈值，以更准确描述0至4分的功能障碍分布及其对应的死亡风险（SOFA-2的AUROC为0.79；95%置信区间为0.76–0.81；SOFA-1的AUROC为0.77；95%置信区间为0.74–0.81）。对ICU第1日至第7日的连续SOFA-2评分评估表明，其预测效度保持稳定。由于数据不足及内容效度欠缺，胃肠及免疫功能障碍评分未被纳入SOFA-2。
> 
> 结论与意义：更新后的SOFA-2评分纳入了当代的器官支持治疗方式及新的评分阈值，能够在一个地理及社会经济背景多样化的大规模重症成人群体中描述器官功能障碍。

### 第二部分 AI 大师评价

本文旨在在国际多中心重症监护数据库基础上，重建并验证更新后的SOFA-2评分体系，以反映现代重症医学的器官功能障碍特征。研究采用联合分析与分阶段Delphi专家共识相结合的设计，涵盖300多万例患者数据，验证了新评分的内容与预测效度。结果显示SOFA-2较原版评分在区分死亡风险方面具有改善。该研究的创新性在于以数据驱动和多区域验证相结合，显著增强了评分的普适性；但胃肠及免疫系统未能纳入仍为未来改进方向。

---

## 23. 人工智能驱动的生活方式干预与人工指导在糖尿病预防项目中的比较：一项随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41144242)
**期刊：** JAMA
**PMID：** 41144242
**DOI：** 10.1001/jama.2025.19563

### 第一部分 原文与翻译

**英文原标题：** An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Prediabetes is common, yet evidence-based lifestyle interventions are underutilized.
> 
> OBJECTIVE: To determine whether referral to an exclusively artificial intelligence (AI)-led lifestyle intervention based on the Diabetes Prevention Program (DPP) is noninferior to referral to a human-led DPP in achieving recommended thresholds for weight loss, hemoglobin A1c (HbA1c) reduction, and weekly physical activity among adults with prediabetes and overweight or obesity.
> 
> DESIGN, SETTING, AND PARTICIPANTS: This phase 3, parallel-group, pragmatic, noninferiority randomized clinical trial was conducted from October 11, 2021, to December 16, 2024 (last follow-up) at 2 US clinical sites in Baltimore, Maryland, and Reading, Pennsylvania. Adults 18 years or older with prediabetes and overweight or obesity were enrolled.
> 
> INTERVENTIONS: Participants were randomized in a 1:1 ratio to receive either a referral to an AI-powered DPP lifestyle intervention delivered via a mobile app and Bluetooth-enabled digital scale or a referral to a human coach-led DPP lifestyle intervention delivered remotely. Both interventions were delivered independently of the study team over a 12-month period.
> 
> MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of maintaining an HbA1c less than 6.5% throughout the study and achievement of at least 5% weight loss, at least 4% weight loss plus at least 150 minutes of weekly physical activity (assessed with actigraphy), or an absolute reduction in HbA1c of at least 0.2 percentage points at 12 months. Noninferiority of referral to the AI-led DPP compared with referral to the human-led DPP was prespecified to be determined if the 1-sided 95% CI lower boundary of the risk difference did not cross -15%.
> 
> RESULTS: A total of 368 participants were included (median [IQR] age, 58 [50-65] years; 71% were female, 27% were Black, 6% were Hispanic, and 61% were White; median [IQR] BMI, 32.3 [28.5-37.1]). After referral, 171 of 183 participants (93.4%) initiated the AI-led DPP and 153 of 185 (82.7%) initiated the human-led DPP. The primary outcome was achieved by 58 of 183 participants (31.7%) in the AI-led DPP group and 59 of 185 (31.9%) in the human-led DPP group (risk difference, -0.2% [1-sided 95% CI, -8.2%]), meeting the criterion for noninferiority. Findings were consistent across individual components of the composite end point and in sensitivity analyses.
> 
> CONCLUSIONS AND RELEVANCE: Among adults with prediabetes and overweight or obesity, referral to a fully automated AI-led DPP was noninferior to referral to a human-led DPP in achieving a composite outcome based on weight reduction, physical activity, and HbA1c.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05056376.

> **中文摘要：**
> 重要性：前驱糖尿病十分常见，但基于证据的生活方式干预仍然未得到充分应用。
> 
> 目的：旨在确定，对于患有前驱糖尿病且超重或肥胖的成年人，是否基于糖尿病预防项目（DPP）的全人工智能（AI）主导生活方式干预，在达到推荐的减重、糖化血红蛋白（HbA1c）下降以及每周体力活动量的阈值方面，不劣于人工指导的DPP干预。
> 
> 设计、场所与参与者：这是一项Ⅲ期、平行组、实用性、非劣效性随机临床试验，于2021年10月11日至2024年12月16日（最后随访）在美国马里兰州巴尔的摩和宾夕法尼亚州雷丁两处临床中心开展。入组对象为年龄18岁及以上、患有前驱糖尿病并伴有超重或肥胖的成年人。
> 
> 干预措施：参与者按1:1比例随机分配至两组：一组接受基于移动应用与蓝牙体重秤的AI驱动DPP生活方式干预；另一组接受远程人工教练主导的DPP生活方式干预。两种干预均由研究团队之外的独立系统在12个月内实施。
> 
> 主要结局及测量指标：主要结局为复合指标，包括在整个研究期间维持HbA1c＜6.5%，并且达到以下之一：体重减轻至少5%；体重减轻至少4%且每周体力活动≥150分钟（以动作感测法评估）；或12个月时HbA1c绝对降低≥0.2个百分点。研究预先设定，若AI组相较人工组的风险差单侧95%置信区间下限未跨越-15%，即判定为非劣效。
> 
> 结果：共纳入368名参与者（中位年龄［四分位距］58［50-65］岁；女性占71%，黑人27%，西班牙裔6%，白人61%；中位体质指数32.3［28.5-37.1］）。转介后，183例中有171例（93.4%）启动了AI组干预，185例中有153例（82.7%）启动了人工组干预。主要结局在AI组183名参与者中有58人（31.7%）达成，在人工组185名中有59人（31.9%）达成（风险差-0.2%［单侧95% CI，-8.2%］），符合非劣效标准。各单项组成及敏感性分析结果一致。
> 
> 结论与意义：在患有前驱糖尿病且超重或肥胖的成年人中，转介至全自动AI主导的DPP干预在达到基于体重下降、体力活动和HbA1c水平的复合结局方面，不劣于人工指导的DPP干预。
> 
> 临床试验注册号：ClinicalTrials.gov编号：NCT05056376。

### 第二部分 AI 大师评价

该研究采用随机、平行组、非劣效性设计，比较人工智能主导与人工指导的糖尿病预防项目在前驱糖尿病人群中的疗效。结果显示，AI驱动的干预在体重减轻、HbA1c下降及体力活动综合结局上不劣于人工指导组。该试验表明，AI可在代谢疾病预防领域实现高水平自主干预，具有极高的可扩展性与成本效益。潜在局限包括研究样本地域及长期依从性评估尚需进一步验证。

---

速递结束，祝您工作愉快！